ATE354592T1 - Vegf-antagonisten zur behandlung von diabetes - Google Patents
Vegf-antagonisten zur behandlung von diabetesInfo
- Publication number
- ATE354592T1 ATE354592T1 AT04758372T AT04758372T ATE354592T1 AT E354592 T1 ATE354592 T1 AT E354592T1 AT 04758372 T AT04758372 T AT 04758372T AT 04758372 T AT04758372 T AT 04758372T AT E354592 T1 ATE354592 T1 AT E354592T1
- Authority
- AT
- Austria
- Prior art keywords
- vegf
- treating diabetes
- vegf antagonists
- blocking
- mediated activity
- Prior art date
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title abstract 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title abstract 6
- 239000005557 antagonist Substances 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 230000000903 blocking effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45879003P | 2003-03-28 | 2003-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE354592T1 true ATE354592T1 (de) | 2007-03-15 |
Family
ID=33131825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04758372T ATE354592T1 (de) | 2003-03-28 | 2004-03-26 | Vegf-antagonisten zur behandlung von diabetes |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7052691B2 (de) |
| EP (1) | EP1608685B1 (de) |
| JP (2) | JP4730909B2 (de) |
| AT (1) | ATE354592T1 (de) |
| AU (1) | AU2004226417B2 (de) |
| BR (1) | BRPI0408749B1 (de) |
| CA (1) | CA2519787C (de) |
| CY (1) | CY1106530T1 (de) |
| DE (1) | DE602004004883T2 (de) |
| DK (1) | DK1608685T3 (de) |
| ES (1) | ES2278333T3 (de) |
| MX (1) | MXPA05008972A (de) |
| PL (1) | PL1608685T3 (de) |
| PT (1) | PT1608685E (de) |
| SI (1) | SI1608685T1 (de) |
| WO (1) | WO2004087206A2 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7378095B2 (en) | 2004-07-30 | 2008-05-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating type I diabetes by blocking VEGF-mediated activity |
| CN102614134B (zh) * | 2005-03-25 | 2016-09-07 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
| RU2432155C3 (ru) | 2006-06-16 | 2017-11-17 | Ридженерон Фармасьютикалз, Инк. | Составы антагониста vegf, подходящие для интравитреального введения |
| ES2345596B1 (es) * | 2009-03-26 | 2011-07-13 | Fundacion Progreso Y Salud | Composicion para la prevencion o el tratamiento de la diabetes mellitus. |
| US20100330098A1 (en) * | 2009-06-29 | 2010-12-30 | Kuo Calvin J | Methods to regulate glucose metabolism |
| MX385629B (es) | 2011-01-13 | 2025-03-18 | Regeneron Pharma | Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos. |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| PE20170142A1 (es) | 2014-01-25 | 2017-04-02 | Chengdu Kanghong Biotechnologies Co Ltd | Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| ES2732925T3 (es) | 2014-07-18 | 2019-11-26 | Sanofi Sa | Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| ITUB20169928A1 (it) * | 2016-01-12 | 2017-07-12 | Medical And Biotechnological Services In Sigla M B S Srl | Formulazioni farmaceutiche per il trattamento del diabete |
| SMT202200374T1 (it) | 2017-11-30 | 2022-11-18 | Regeneron Pharma | Uso di un antagonista del vegf per trattare disturbi angiogenici dell’occhio |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9410533D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | In situ hybridisation and immuno-Chemical localisation of a growth factor |
| WO2000064946A2 (en) * | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| CA2376379C (en) | 1999-06-08 | 2007-08-07 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
-
2004
- 2004-03-26 AU AU2004226417A patent/AU2004226417B2/en not_active Ceased
- 2004-03-26 EP EP04758372A patent/EP1608685B1/de not_active Expired - Lifetime
- 2004-03-26 US US10/811,170 patent/US7052691B2/en not_active Expired - Lifetime
- 2004-03-26 JP JP2006509325A patent/JP4730909B2/ja not_active Expired - Fee Related
- 2004-03-26 DK DK04758372T patent/DK1608685T3/da active
- 2004-03-26 MX MXPA05008972A patent/MXPA05008972A/es active IP Right Grant
- 2004-03-26 CA CA2519787A patent/CA2519787C/en not_active Expired - Fee Related
- 2004-03-26 SI SI200430312T patent/SI1608685T1/sl unknown
- 2004-03-26 DE DE602004004883T patent/DE602004004883T2/de not_active Expired - Lifetime
- 2004-03-26 PT PT04758372T patent/PT1608685E/pt unknown
- 2004-03-26 WO PCT/US2004/009246 patent/WO2004087206A2/en not_active Ceased
- 2004-03-26 PL PL04758372T patent/PL1608685T3/pl unknown
- 2004-03-26 ES ES04758372T patent/ES2278333T3/es not_active Expired - Lifetime
- 2004-03-26 BR BRPI0408749A patent/BRPI0408749B1/pt not_active IP Right Cessation
- 2004-03-26 AT AT04758372T patent/ATE354592T1/de active
-
2007
- 2007-04-19 CY CY20071100538T patent/CY1106530T1/el unknown
-
2010
- 2010-10-20 JP JP2010235790A patent/JP2011037894A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SI1608685T1 (sl) | 2007-08-31 |
| PT1608685E (pt) | 2007-05-31 |
| WO2004087206A2 (en) | 2004-10-14 |
| ES2278333T3 (es) | 2007-08-01 |
| BRPI0408749B1 (pt) | 2016-10-04 |
| JP4730909B2 (ja) | 2011-07-20 |
| EP1608685A2 (de) | 2005-12-28 |
| WO2004087206A3 (en) | 2004-12-16 |
| DK1608685T3 (da) | 2007-06-11 |
| HK1080092A1 (en) | 2006-04-21 |
| CA2519787C (en) | 2012-06-05 |
| MXPA05008972A (es) | 2005-11-04 |
| CA2519787A1 (en) | 2004-10-14 |
| AU2004226417B2 (en) | 2009-01-22 |
| BRPI0408749A (pt) | 2006-03-28 |
| JP2006521397A (ja) | 2006-09-21 |
| US7052691B2 (en) | 2006-05-30 |
| US20040213787A1 (en) | 2004-10-28 |
| DE602004004883D1 (de) | 2007-04-05 |
| PL1608685T3 (pl) | 2007-07-31 |
| CY1106530T1 (el) | 2012-01-25 |
| DE602004004883T2 (de) | 2007-11-15 |
| AU2004226417A1 (en) | 2004-10-14 |
| EP1608685B1 (de) | 2007-02-21 |
| JP2011037894A (ja) | 2011-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE354592T1 (de) | Vegf-antagonisten zur behandlung von diabetes | |
| ATE387194T1 (de) | Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung | |
| ATE451930T1 (de) | Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis | |
| NO20070506L (no) | Fremgangsmater og mellomprodukter nyttige for fremstilling av kondenserte heterocykliske kinase inhibitorer. | |
| ATE321048T1 (de) | Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und - tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes | |
| ATE551059T1 (de) | Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie | |
| DE602005009318D1 (de) | Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren | |
| ATE499097T1 (de) | Monozyklische heterozyklen als kinase-hemmer | |
| ATE506456T1 (de) | Verfahren zur behandlung von lentivirusinfektionen | |
| ATE404574T1 (de) | Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden | |
| EA200870029A1 (ru) | Способ применения антагонистов il-6 с ингибиторами протеасом | |
| ATE419253T1 (de) | Inhibitoren von thienopyridin- und furopyridinkinase | |
| ATE554087T1 (de) | Neue kinaseinhibitoren | |
| DE60039783D1 (de) | Lfa-1 antagonisten und tnf-alpha antagonisten zur | |
| ATE555803T1 (de) | Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen | |
| MX2007001241A (es) | Metodos para tratar diabetes tipo i mediante el bloqueo de la actividad mediada de vegf. | |
| WO2003037310A3 (en) | Use of inhibitors of the abc drug transporter to increase the activity of anti-microbial agents | |
| ATE359283T1 (de) | Substituierte pyrazinonverbindungen zur behandlung von entzündungen | |
| ATE443044T1 (de) | Tace inhibitoren | |
| DE502005007105D1 (de) | 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü-pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren | |
| EA200800766A1 (ru) | Ингибиторы pi3k для лечения эндометриоза | |
| ATE333869T1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
| DE60229123D1 (de) | Behandlung von fibromyalgie mit pindolol | |
| DE60329000D1 (de) | C-terminale globulardomäne von adiponectin zur behandlung von arteriosklerose | |
| ATE438859T1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1608685 Country of ref document: EP |